Literature DB >> 6322163

Transformation by polyoma virus is drastically reduced by substitution of phenylalanine for tyrosine at residue 315 of middle-sized tumor antigen.

G Carmichael, B S Schaffhausen, G Mandel, T J Liang, T L Benjamin.   

Abstract

We used an oligonucleotide to introduce an A----T transversion at nucleotide position 1178 in polyoma virus DNA. The single effect of this mutation is to substitute phenylalanine for tyrosine at residue 315 of the middle-sized tumor (mT) protein (antigen). This site was previously identified as a major phosphate acceptor in the protein kinase reaction of immunocomplexes containing mT antigen. Reconstituted polyoma virus with the transversion, Py-1178-T, produces an altered mT protein that shows about 20% of the activity of wild-type mT antigen in the immunocomplex kinase assay. This residual activity appears to be directed primarily at another tyrosine at position 322 in the mT protein. The transforming ability of Py-1178-T is drastically reduced compared to wild-type virus. The efficiency of transformation by the mutant is less than 1% of that of wild type in focus assays and less than 0.1% in soft-agar growth assays. Cells identified in focus assays with Py-1178-T are generally less transformed in their phenotype than wild-type transformed cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322163      PMCID: PMC344898          DOI: 10.1073/pnas.81.3.679

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  AGAR SUSPENSION CULTURE FOR THE SELECTIVE ASSAY OF CELLS TRANSFORMED BY POLYOMA VIRUS.

Authors:  I MACPHERSON; L MONTAGNIER
Journal:  Virology       Date:  1964-06       Impact factor: 3.616

2.  Analysis of host range of nontransforming polyoma virus mutants.

Authors:  E Goldman; T L Benjamin
Journal:  Virology       Date:  1975-08       Impact factor: 3.616

3.  Protein kinase activity associated with the avian sarcoma virus src gene product.

Authors:  M S Collett; R L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

4.  Tumor antigen(s) in cell productively infected by wild-type polyoma virus and mutant NG-18.

Authors:  B S Schaffhausen; J E Silver; T L Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

5.  Tumor antigens induced by nontransforming mutants of polyoma virus.

Authors:  J Silver; B Schaffhausen; T Benjamin
Journal:  Cell       Date:  1978-10       Impact factor: 41.582

6.  Comparison of phosphorylation of two polyoma virus middle T antigens in vivo and in vitro.

Authors:  B Schaffhausen; T L Benjamin
Journal:  J Virol       Date:  1981-10       Impact factor: 5.103

7.  Rous sarcoma virus transforming protein, p60src, expressed in E. coli, functions as a protein kinase.

Authors:  T M Gilmer; R L Erikson
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

8.  Requirement for the C-terminal region of middle T-antigen in cellular transformation by polyoma virus.

Authors:  U Novak; B E Griffin
Journal:  Nucleic Acids Res       Date:  1981-05-11       Impact factor: 16.971

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Transformation of rat cells by an altered polyoma virus genome expressing only the middle-T protein.

Authors:  R Treisman; U Novak; J Favaloro; R Kamen
Journal:  Nature       Date:  1981-08-13       Impact factor: 49.962

View more
  47 in total

Review 1.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

2.  Tumor induction by a transformation-defective polyoma virus mutant blocked in signaling through Shc.

Authors:  R Bronson; C Dawe; J Carroll; T Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Interactions of polyomavirus middle T with the SH2 domains of the pp85 subunit of phosphatidylinositol-3-kinase.

Authors:  M Yoakim; W Hou; Y Liu; C L Carpenter; R Kapeller; B S Schaffhausen
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Functional asymmetry of the regions juxtaposed to the membrane-binding sequence of polyomavirus middle T antigen.

Authors:  J Dahl; U Thathamangalam; R Freund; T L Benjamin
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

5.  12-O-tetradecanoylphorbol-13-acetate stimulates phosphorylation of the 58,000-Mr form of polyomavirus middle T antigen in vivo: implications for a possible role of protein kinase C in middle T function.

Authors:  J T Matthews; T L Benjamin
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

Review 6.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

7.  Studies of partially transforming polyomavirus mutants establish a role for phosphatidylinositol 3-kinase in activation of pp70 S6 kinase.

Authors:  J Dahl; R Freund; J Blenis; T L Benjamin
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

8.  Signaling from polyomavirus middle T and small T defines different roles for protein phosphatase 2A.

Authors:  K P Mullane; M Ratnofsky; X Culleré; B Schaffhausen
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

9.  Phosphorylation in vitro of Escherichia coli-produced 235R and 266R tumor antigens encoded by human adenovirus type 12 early transformation region 1A.

Authors:  L A Lucher; P M Loewenstein; M Green
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

10.  Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.

Authors:  Cecile Rouleau; Arun T Pores Fernando; Justin H Hwang; Nathalie Faure; Tao Jiang; Elizabeth A White; Thomas M Roberts; Brian S Schaffhausen
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.